GlassScriptPhysician profile
Katrina P Lock
NPI 1245505585
$4,686.17
in general payments reported to CMS, 2019-2025
50 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $793 · 2023: $2,934 · 2024: $685 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,505 · Education: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,504.52 |
| Education | $388.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.86 | 2022-2025 | |
| Janssen Biotech, INC. | $394.25 | 2022-2023 | Rybrevant, Darzalex, Imbruvica |
| Novartis Pharmaceuticals Corporation | $390.80 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $361.06 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $336.04 | 2023 | Jakafi, Pemazyre, Monjuvi |
| Celgene Corporation | $230.03 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $223.09 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $214.06 | 2023-2024 | Reblozyl, Opdivo |
| Lilly USA, LLC | $176.62 | 2022-2023 | Jaypirca, Verzenio |
| Astrazeneca Pharmaceuticals LP | $130.60 | 2023 | Enhertu, Lynparza |
| Convatec INC. | $117.59 | 2024 | |
| Daiichi Sankyo INC. | $114.98 | 2022-2024 | Enhertu, Injectafer |
| Karyopharm Therapeutics INC. | $108.82 | 2022-2023 | Xpovio |
| Genzyme Corporation | $102.83 | 2022-2023 | |
| Eisai INC. | $96.04 | 2022-2024 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $89.18 | 2022-2023 | Cabometyx |
| Genentech USA, INC. | $80.04 | 2022-2024 | Tecentriq, Venclexta |
| Aveo Pharmaceuticals, INC. | $64.99 | 2023 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $56.70 | 2022-2024 | Libtayo |
| Coherus Oncology, INC. | $52.99 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.74 | 2022-2023 | Alunbrig, Ninlaro |
| Myriad Genetic Laboratories, INC. | $48.18 | 2022 | |
| Servier Pharmaceuticals LLC | $46.47 | 2023-2024 | |
| Organon LLC | $46.43 | 2022-2023 | Renflexis, Ontruzant |
| Bayer Healthcare Pharmaceuticals INC. | $42.71 | 2023 | |
| Seagen INC. | $42.62 | 2022-2023 | Tukysa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.94 | 2022-2023 | Gilotrif |
| Array Biopharma INC | $38.79 | 2023 | Lorbrena, Xalkori, Mektovi |
| Puma Biotechnology, INC. | $34.73 | 2023-2024 | |
| Kyowa Kirin, INC. | $32.87 | 2023 | Poteligeo |
| Amgen INC. | $31.10 | 2022 | |
| Rigel Pharmaceuticals, INC. | $30.96 | 2023-2024 | Rezlidhia, Tavalisse |
| Adc Therapeutics America, INC. | $30.86 | 2023 | |
| Alexion Pharmaceuticals, INC. | $30.13 | 2023 | Ultomiris |
| Blue Earth Diagnostics | $27.43 | 2022-2023 | |
| Medline Industries LP | $26.72 | 2024 | Medline |
| Beigene USA, INC. | $24.11 | 2023 | Brukinsa |
| Gilead Sciences, INC. | $22.45 | 2024 | |
| Adaptive Biotechnologies Corporation | $18.27 | 2023 | Clonoseq |
| Digestive Care, INC. | $17.67 | 2023 | Pertzye |
| Morphosys, US INC. | $16.48 | 2024 | Monjuvi |
| Grifols USA, LLC | $15.56 | 2023 | Thrombate III |
| Sobi, INC | $15.12 | 2023 | |
| Mirati Therapeutics, INC. | $14.31 | 2023 | Krazati |
| Genmab U.S., INC. | $14.29 | 2023 | Tivdak |
| Taiho Oncology, INC. | $14.17 | 2022 | |
| Fresenius Kabi USA, LLC | $13.92 | 2023 | Stimufend |
| G1 Therapeutics, INC. | $13.72 | 2023 | Cosela |
| Agios Pharmaceuticals, INC. | $13.43 | 2023 | Pyrukynd |
| Tersera Therapeutics LLC | $13.42 | 2023 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Lock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.